Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease

Advances in Experimental Medicine and Biology

Volumn 579, Issue , 2006, Pages 209-218

  Braun, Jonathan ^a   Targan, Stephan R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODY FORMATION; BACTERIAL INFECTIONS; HUMANS; IMMUNOGENETICS; INFLAMMATORY BOWEL DISEASES; MYCOSES;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 33745754561     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-33778-4_13     Document Type: Review

References (92)

1. Starzl TE, Zinkernagel RM. Mechanisms of Disease: Antigen localization and migration in immunity and tolerance. N Engl J Med 1998; 339(26):1905-1913.
2. Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216.
3. Sartor RB. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol 1997; 148:567-576.
4. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20:495-549.
5. Covacci A, Telford JL, Del Giudice G et al. Helicobacter pylori virulence and genetic geography. Science 1999; 284:1328-1333.
6. Torsvik V, Ovreas L. Microbial diversity and function in soil: From genes to ecosystems. Curr Opin Microbiol 2002; 5(3):240-245.
7. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124(2):521-536.
8. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411(6837):599-603.
9. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411(6837):603-606.
10. Inohara N, Nunez G. NODs: Intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3(5):371-382.
11. Bonen DK, Ogura Y, Nicolae DL et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003; 124(1):140-146.
12. Satsangi J, Parkes M, Jewell DP et al. Genetics of inflammatory bowel disease. Clin Sci 1998; 94(5):473-478.
13. Cuthbert AP, Fisher SA, Mirza MM et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122(4):867-874.
14. Abreu MT, Taylor KD, Lin YC et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123(3):679-688.
15. Ahmad T, Armuzzi A, Bunce M et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122(4):854-866.
16. Halfvarson J, Bodin L, Tysk C et al. Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003; 124(7):1767-1773.
17. Hisamatsu T, Suzuki M, Reinecker HC et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124(4):993-1000.
18. Giallourakis C, Stoll M, Miller K et al. IBD5 is a general risk factor for inflammatory bowel disease: Replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am J Hum Genet 2003; 73(1):205-211.
19. Curran ME, Lau KF, Hampe J et al. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 1998; 115(5):1066-1071.
20. Parkes M, Satsangi J, Jewell DP et al. Ulcerative colitis is more strongly linked to chromosome 12 than Crohn's disease. Gut 2001; 49(2):311.
21. Bouma G, Oudkerk P, Crusius JB et al. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD). Clinical and Experimental Immunology 1997; 109(1):175-179.
22. Naom I, Lee J, Ford D et al. Analysis of the contribution of HLA genes to genetic predisposition in inflammatory bowel disease. American Journal of Human Genetics 1996; 59(1):226-233.
23. Yang H-Y, Rotter JI, Toyoda H et al. Ulcerative colitis: A genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92(2):1080-1084.
24. Taylor KD, Plevy SE, Yang H et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120(6):1347-1355.
25. Ghanim H, Garg R, Aljada A et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86(3):1306-1312.
26. Joseph SB, Castrillo A, Laffitte BA et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9(2):213-219.
27. Dubuquoy L, Jansson EA, Deeb S et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003; 124(5):1265-1276.
28. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci USA 2002; 99(24):15451-15455.
29. Fellermann K, Wehkamp J, Herrlinger KR et al. Crohn's disease: A defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003; 15(6):627-634.
30. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270:1203-1207.
31. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161(10):5733-5744.
32. Schwab M, Schaeffeler E, Marx C et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124(1):26-33.
33. Yacyshyn B, Maksymowych W, Bowen-Yacyshyn MB. Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis. Hum Immunol 1999; 60(8):677-687.
34. Kakazu T, Hara J, Matsumoto T et al. Type 1 T-helper cell predominance in granulomas of Crohn's disease. Am J Gastroenterol 1999; 94(8):2149-2155.
35. Neurath MF, Weigmann B, Finotto S et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002; 195(9):1129-1143.
36. Dohi T, Fujihashi K, Kiyono H et al. Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. Gastroenterology 2000; 119(3):724-733.
37. Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157:1261-1270.
38. Uguccioni M, Gionchetti P, Robbiani DF et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. American Journal of Pathology 1999; 155(2):331-336.
39. Boirivant M, Fuss IJ, Chu A et al. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998; 188(10):1929-1939.
40. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348(1):24-32.
41. Blaser MJ, Miller RA, Lacher J et al. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 1984; 87:888-894.
42. Auer IO, Roder A, Wensinck F et al. Selected bacterial antibodies in Crohn's disease and ulcerative colitis. Scandinavian Journal of Gastroenterology 1983; 18(2):217-223.
43. O'Mahony S, Anderson N, Nuki G et al. Systemic and mucosal antibodies to Klebsiella in patients with ankylosing spondylitis and Crohn's disease. Ann Rheum Dis 1992; 51:1296-1300.
44. Braun J. Unsettling facts of life: Bacterial commensalism, epithelial adherence, and inflammatory bowel disease. Gastroenterology 2002; 122(1):228-230.
45. McKenzie H, Main J, Pennington CR et al. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 1990; 31:536-538.
46. Barnes RMR, Allan S, Taylor-robinson CH et al. Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: Is IgA antibody a marker for Crohn's disease. Int Arch Allergy Appl Immunol 1990; 92:9-15.
47. Sendid B, Colombel JF, Jacquinot PM et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diag Lab Immunol 1996; 3:219-226.
48. Davidson IW, Lloyd RS, Whorewell PJ et al. Antibodies to maize in patients with Crohn's disease, ulcerative colitis, and coeliac disease. Clin Exp Immunol 1979; 35:147-148.
49. Sonnenberg A. Occupational distribution of inflammatory bowel disease among German employees. Gut 1990; 31:1037-1040.
50. Quinton JF, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut 1998; 42(6):788-791.
51. Sutton C, Yang H-Y, Rotter JI et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies (ASCA) in affected and unaffected relatives of Crohn's disease patients. Gut 2000; 46:58-63.
52. Wayne LG, Hollander D, Anderson B et al. Immunoglobulin A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. J Clin Microbiol 1992; 30:2013-2018.
53. Vannuffel P, Dieterich C, Naerhuyzen B et al. Occurrence, in Crohn's disease, of antibodies directed against a species-specific recombinant polypeptide of Mycobacterium paratuberculosis. Clin Diag Lab Immunol 1994; 1:241-243.
54. Elsaghier A, Prantera C, Moreno C et al. Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease. Clin Exp Immunol 1992; 90:503-508.
55. Suenaga K, Yokoyama Y, Nishimori I et al. Serum antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease. Dig Dis Sci 1999; 44(6):1202-1207.
56. Cohavy O, Harth G, Horwitz MA et al. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum IgA from patients with Crohn's disease. Infect Immun 1999; 67:6510-6517.
57. El Zlaatari FA, Naser SA, Hulten K et al. Characterization of Mycobacterium paratuberculosis p36 antigen and its seroreactivities in Crohn's disease. Curr Microbiol 1999; 39(2):115-119.
58. Naser SA, Hulten K, Shafran I et al. Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet Microbiol 2000; 77(3-4):497-504.
59. Collins MT, Lisby G, Moser C et al. Results of multiple diagnostic tests for Mycobacterium avium subsp. Paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol 2000; 38(12):4373-4381.
60. Cohavy O, Bruckner D, Eggena ME et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000; 68:1542-1548.
61. Wei B, Dalwadi H, Gordon LK et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein associated with inflammatory bowel disease. Infect Immun 2001; 69(10):6044-6054.
62. Landers CJ, Cohavy O, Misra R et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002; 123(3):689-699.
63. Sutton CL, Kim J, Yamane A et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000; 119:23-28.
64. Wei B, Huang T, Dalwadi H et al. Pseudomonas fluorescens Encodes the Crohn's Disease-Associated I2 Sequence and T-Cell Superantigen. Infect Immun 2002; 70(12):6567-6575.
65. Dalwadi H, Wei B, Kronenberg M et al. The Crohn's disease-associated bacterial protein I2 is a novel enteric T cell superantigen. Immunity 2001; 15(1): 149-158.
66. Duchmann R, May E, Heike M et al. T cell specificity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999; 44(6):812-818.
67. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347(6):417-429.
68. Papadakis KA, Prehn J, Moreno ST et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001; 121(2):246-254.
69. Kunkel EJ, Kim CH, Lazarus NH et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest 2003; 111(7):1001-1010.
70. Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111(8):1133-1145.
71. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3(2):81-92.
72. Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122(4):904-915.
73. Rump JA, Scholmerich J, Gross V et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990; 181(4-5):406-413.
74. Duerr RH, Targan SR, Landers CJ et al. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 1991; 100:1590-1596.
75. Billing P, Tahir S, Calfin B et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995; 147:979-987.
76. Vidrich A, Lee J, James E et al. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: Ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995; 15:293-299.
77. Folwaczny C, Noehl N, Endres SP et al. Antinuclear autoantibodies in patients with inflammatory bowel disease - High prevalence in first-degree relatives. Dig Dis Sci 1997; 42(8):1593-1597.
78. Eggena M, Cohavy O, Parseghian M et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmunity 2000; 14:83-97.
79. Reumaux D, Meziere C, Colombel J-F et al. Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn's disease. Clin Immunol Immunopathol 1995; 77:349-357.
80. Sobajima J, Ozaki S, Uesugi H et al. High mobility group (HMG) nonhistone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis. Gut 1999; 44(6):867-873.
81. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110(7):955-963.
82. Aldebert D, Masy E, Reumaux D et al. Immunoglobulin G subclass distribution of anti-endothelial cell antibodies (AECA) in patients with ulcerative colitis and Crohn's disease. Dig Dis Sci 1997; 42:2350-2355.
83. Stevens TR, Harley SL, Groom JS et al. Anti-endothelial cell antibodies in inflammatory bowel disease. Dig Dis Sci 1993; 38:426-432.
84. Yang P, Jarnerot G, Danielsson D et al. P-ANCA in monozygotic twins with inflammatory bowel disease. Gut 1995; 36(6):887-890.
85. Bhan AK, Mizoguchi E, Smith RN et al. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999; 169:195-207.
86. Satsangi J, Landers CJ, Welsh KI et al. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998; 4(1):18-26.
87. Vasiliauskas EA, Kam LY, Karp LC et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47(4):487-496.
88. Fiocchi C, Roche JK, Michener WM. High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives. Ann Int Med 1989; 110:786-794.
89. Brandtzaeg P, Halstensen TS, Kett K et al. Immunobiology and immunopathology of human gut mucosa: Humoral immunity and intraepithelial lymphocytes. Gastroenterology 1989; 97:1562-1584.
90. Geng X, Biancone L, Dai HH et al. Tropomyosin isoforms in intestinal mucosa: Production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 1998; 114(5):912-922.
91. Sakamaki S, Takayanagi N, Yoshizaki N et al. Autoantibodies against the specific epitope of human tropomyosin(s) detected by a peptide based enzyme immunoassay in sera of patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPw9 transfected L cells. Gut 2000; 47(2):236-24l.
92. Ohman L, Franzen L, Rudolph U et al. Immune activation in the intestinal mucosa before the onset of colitis in Galphai2-deficient mice. Scand J Immunol 2000; 52(1):80-90.